Systematic-Review-Drug-Efficiency-Dissertation-Sample-Work-Tutors-India
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
Idiopathic Pulmonary Fibrosis (IPF) as the name suggests is a progressive disorder with no known aetiology. It is characterised by the thickening of the alveoli due to scarring resulting in cough. It is known to primarily occur in older adults over 60 years of age. The findings of IPF have a known association of Usual Interstitial Pneumonia (UIP) (Raghu et al., 2011; Kawano-Dourado & Kairalla, 2013; Wells, 2013). It has been deemed that the prognosis is generally poor when UIP has been confirmed (King et al., 2001b). The median survival rate of IPF is 50%, typically around two years after diagnosis (Raghu et al., 2011; King et al., 2001b).
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
3.4.1 Inclusion criteria<br />
The inclusion criteria set for the selection of studies are as follows:<br />
‣ Randomised Controlled Trial (RCT) studies related to efficacy of Pirfenidone with<br />
N-acetylcysteine<br />
‣ Studies wherein the population are defined with intervention and control groups<br />
both being patients with IPF<br />
‣ Studies which assessed the efficacy of Pirfenidone with N-acetylcysteine as a<br />
combined drug therapy<br />
‣ Studies in English language<br />
‣ Studies within the time frame of 2006-2016<br />
‣ Studies which assessed the efficacy of Pirfenidone with N-acetylcysteine as<br />
intervention and control groups which could be administered with any drug<br />
treatment modality such as single drug therapy, combination of placebo and a<br />
drug or only with a placebo<br />
3.4.2 Exclusion criteria<br />
The exclusion criteria set for the selection of studies are as follows:<br />
‣ Studies which were not conducted within the selected time-frame (2006-2016)<br />
‣ Studies which assessed the efficacy of more than two drugs and drug treatment<br />
other than the combination of pirfenidone and NAC were excluded<br />
‣ Studies which were not in English language<br />
‣ Studies which were not RCTs<br />
‣ Studies which assessed the efficacy of Pirfenidone with N-acetylcysteine for some<br />
other diseases other than IPF<br />
3.4.3 Assessment of bias risk and methodological quality<br />
Any meta-analysis requires the assessment of quality of methodology used and bias<br />
risk as such analysis acts as a tool for determination of the weaknesses of the study which<br />
might affect the results of the analysis (Higgins & Altman, 2008). There are two different<br />
types of validity which include internal and external validity. The internal validity is used to<br />
© 2017-2018 All Rights Reserved, No part of this document should be modified/used without prior consent<br />
<strong>Tutors</strong> <strong>India</strong> - Your trusted mentor since 2001<br />
www.tutorindia.com I UK # +44-1143520021, info@tutorsindia.com<br />
Page 63 of 172
Change language